GLYCOPYRROLATE

Post-LOE

glycopyrrolate

ANDAORALTABLET
Approved
Oct 2011
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
5

Clinical Trials (5)

NCT07132983Phase 2Completed

A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease

Started Oct 2025
33 enrolled
Chronic Obstructive Pulmonary Disease
NCT07016412Phase 2Recruiting

A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD

Started Jul 2025
480 enrolled
Chronic Obstructive Pulmonary Disease
NCT06545500Phase 2Completed

A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD

Started Aug 2024
46 enrolled
Chronic Obstructive Pulmonary Disease
NCT05887375Phase 4Enrolling By Invitation

Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery

Started Aug 2023
118 enrolled
Spine SurgeryReversal of Neuromuscular BlockadeUrinary Retention Postoperative
NCT00558285Phase 2Completed

Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Started Nov 2007
257 enrolled
Chronic Obstructive Pulmonary Disease (COPD)